|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a genetic approach, we show that recruitment of the p160 class of coactivators is sufficient for gene activation and for the growth stimulatory actions of estrogen in breast cancer supporting a model in which ER cofactors play unique roles in estrogen signaling.
|
11136970 |
2000 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These findings suggest that PELP1 is a novel coregulator of ERalpha and may have a role in breast cancer tumorigenesis.
|
11481323 |
2001 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The p160 nuclear receptor coactivator, AIB1 (amplified in breast cancer 1), is frequently amplified and overexpressed in human breast cancer and has been shown to enhance estrogen-dependent transactivation.
|
12964942 |
2003 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression or amplification of ACTR (also named AIB1, RAC3, p/CIP, TRAM-1, and SRC-3), a member of the p160 family of coactivators for nuclear hormone receptors, has been frequently detected in multiple types of human tumors, including breast cancer.
|
15169882 |
2004 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12.
|
15917309 |
2005 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical analysis of PELP1 expression using a tumor progression array of 252 breast carcinomas and normal breast tissue specimens revealed that PELP1 expression is deregulated to a greater degree in higher grade node-positive invasive tumors than in normal breast tissue or ductal carcinoma in situ.
|
17545633 |
2007 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a tritiated-water release assay, we demonstrated that MCF7-PELP1 clones exhibit increased aromatase activity compared with control MCF-7 cells.
|
18079323 |
2008 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The p160 nuclear receptor coactivator, AIB1 (amplified in breast cancer 1), is frequently overexpressed in human breast cancer and has been shown to be associated with tamoxifen resistance.
|
18827493 |
2008 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unique roles of p160 coactivators for regulation of breast cancer cell proliferation and estrogen receptor-alpha transcriptional activity.
|
19095746 |
2009 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AIB1 (amplified in breast cancer 1), also called SRC-3 and NCoA-3, is a member of the p160 nuclear receptor co-activator family and is considered an important oncogene in breast cancer.
|
19418218 |
2009 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, PELP1 protein expression is an independent prognostic predictor of shorter BCSS and DFI in breast cancer and its elevated expression is positively associated with markers of poor outcome.
|
19495959 |
2010 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because the expression of both PELP1 and CDKs is deregulated in breast tumors, CDK-PELP1 interactions will have implications in breast cancer progression.
|
20807815 |
2010 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Distinctive functions of p160 steroid receptor coactivators in proliferation of an estrogen-independent, tamoxifen-resistant breast cancer cell line.
|
21059860 |
2011 |
|
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AIB1 (amplified in breast cancer I) is a member of the p160 steroid receptor coactivator family.
|
22035181 |
2011 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest inhibition of PELP1-KDM1-mediated histone modifications as a potential therapeutic strategy for blocking breast cancer progression and therapy resistance.
|
22812534 |
2012 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Integration of ERα-PELP1-HER2 signaling by LSD1 (KDM1A/AOF2) offers combinatorial therapeutic opportunities to circumventing hormone resistance in breast cancer.
|
22992372 |
2012 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The ERα coregulator PELP1 plays an important role in ERα signaling and is a proto-oncogene with aberrant expression in breast cancer.
|
23486015 |
2013 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PELP1 (proline, glutamic acid and leucine rich protein 1) is a nuclear receptor coregulator that is upregulated during breast cancer progression to metastasis and is an independent prognostic predictor of shorter survival of breast cancer patients.
|
23975430 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pathway analysis revealed that PELP1 modulates several pathways including the molecular mechanisms of cancer, estrogen signaling, and breast cancer progression.
|
24447537 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, ER/PR/PELP1 complexes were also detected in human breast cancer samples.
|
24469035 |
2015 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of PELP1 in Chinese women with primary breast cancer appears to be associated with biomarkers of poor outcome; these results are similar to other reports based on Western populations.
|
24627205 |
2014 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PELP1 expression is upregulated in breast cancer, contributes to therapy resistance, and is a prognostic marker of poor survival.
|
24688046 |
2014 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, the in vivo significance of PELP1 deregulation during initiation and progression of breast cancer remains unknown.
|
25377474 |
2014 |
|
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
PELP1 phosphorylation was significantly greater in the TNBC tumors than in the other subtypes of breast cancer and in the normal tissues.
|
25788226 |
2015 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we tested for PELP1 localization in breast epithelial cells from women at high risk for developing breast cancer and found that PELP1 was localized to the cytoplasm in 36% of samples.
|
25789479 |
2015 |